JP2023106433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023106433A5 JP2023106433A5 JP2023075458A JP2023075458A JP2023106433A5 JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5 JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023075458 A JP2023075458 A JP 2023075458A JP 2023106433 A5 JP2023106433 A5 JP 2023106433A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 59
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 12
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 12
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 12
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 208000000389 T-cell leukemia Diseases 0.000 claims 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000009277 hairy cell leukemia Diseases 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 101100404851 Macaca fascicularis KLRK1 gene Proteins 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000001608 potassium adipate Substances 0.000 claims 1
- 239000001601 sodium adipate Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025092507A JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539421P | 2017-07-31 | 2017-07-31 | |
| US62/539,421 | 2017-07-31 | ||
| JP2020505208A JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505208A Division JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092507A Division JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023106433A JP2023106433A (ja) | 2023-08-01 |
| JP2023106433A5 true JP2023106433A5 (enExample) | 2023-12-01 |
Family
ID=65233032
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505208A Pending JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2023075458A Pending JP2023106433A (ja) | 2017-07-31 | 2023-05-01 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505208A Pending JP2020529410A (ja) | 2017-07-31 | 2018-07-31 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025092507A Pending JP2025131681A (ja) | 2017-07-31 | 2025-06-03 | Ｎｋｇ２ｄ、ｃｄ１６及びｆｌｔ３と結合するタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20200165344A1 (enExample) |
| EP (1) | EP3661554A4 (enExample) |
| JP (3) | JP2020529410A (enExample) |
| KR (2) | KR20250051800A (enExample) |
| CN (1) | CN111132698A (enExample) |
| AU (2) | AU2018309712A1 (enExample) |
| BR (1) | BR112020001972A2 (enExample) |
| CA (1) | CA3070986A1 (enExample) |
| CO (1) | CO2020001981A2 (enExample) |
| EA (1) | EA202090387A1 (enExample) |
| IL (1) | IL272374A (enExample) |
| MA (1) | MA49769A (enExample) |
| MX (1) | MX2020001257A (enExample) |
| SG (1) | SG11202000632QA (enExample) |
| WO (1) | WO2019028027A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| CA3235295C (en) | 2017-02-20 | 2024-11-19 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| US12384847B2 (en) | 2018-02-08 | 2025-08-12 | Dragonfly Therapeutics, Inc. | Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigen |
| US12215157B2 (en) | 2018-02-20 | 2025-02-04 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use |
| CN112074532B (zh) | 2018-03-27 | 2025-02-28 | 修普霍斯生物科学有限公司 | 结合非天然NKG2D受体的非天然NKG2D配体的修饰的α1-α2结构域 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MA53284A (fr) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| EA202191650A1 (ru) | 2018-12-18 | 2021-10-22 | Бёрингер Ингельхайм Ио Канада Инк. | Flt3 агонистические антитела и их применения |
| PE20221316A1 (es) * | 2019-10-15 | 2022-09-07 | Dragonfly Therapeutics Inc | Proteinas que se unen a nkg2d, cd16 y flt3 |
| KR20220144841A (ko) * | 2020-02-21 | 2022-10-27 | 하푼 테라퓨틱스, 인크. | Flt3 결합 단백질 및 사용 방법 |
| TW202208428A (zh) | 2020-05-06 | 2022-03-01 | 美商蜻蜓醫療公司 | 結合ｎｋｇ２ｄ、ｃｄ１６及ｃｌｅｃ１２ａ之蛋白質 |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3102679A1 (en) * | 2007-12-14 | 2009-06-25 | Birgitte Urso | Antibodies against human nkg2d and uses thereof |
| AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| HRP20160422T1 (hr) * | 2009-12-23 | 2016-05-20 | Synimmune Gmbh | Protutijela protiv flt3 postupci njihove upotrebe |
| UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CN104203981A (zh) * | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| EP2862875B1 (en) * | 2012-06-14 | 2023-09-06 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION |
| EP3126384B1 (en) * | 2014-04-01 | 2020-12-02 | Adimab, LLC | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
-
2018
- 2018-07-31 BR BR112020001972-0A patent/BR112020001972A2/pt not_active Application Discontinuation
- 2018-07-31 CN CN201880062880.1A patent/CN111132698A/zh active Pending
- 2018-07-31 KR KR1020257011280A patent/KR20250051800A/ko active Pending
- 2018-07-31 JP JP2020505208A patent/JP2020529410A/ja active Pending
- 2018-07-31 EP EP18840650.8A patent/EP3661554A4/en active Pending
- 2018-07-31 WO PCT/US2018/044610 patent/WO2019028027A1/en not_active Ceased
- 2018-07-31 AU AU2018309712A patent/AU2018309712A1/en not_active Abandoned
- 2018-07-31 SG SG11202000632QA patent/SG11202000632QA/en unknown
- 2018-07-31 MA MA049769A patent/MA49769A/fr unknown
- 2018-07-31 MX MX2020001257A patent/MX2020001257A/es unknown
- 2018-07-31 US US16/635,079 patent/US20200165344A1/en not_active Abandoned
- 2018-07-31 KR KR1020207005238A patent/KR20200033302A/ko not_active Ceased
- 2018-07-31 EA EA202090387A patent/EA202090387A1/ru unknown
- 2018-07-31 CA CA3070986A patent/CA3070986A1/en active Pending
-
2020
- 2020-01-30 IL IL272374A patent/IL272374A/en unknown
- 2020-02-25 CO CONC2020/0001981A patent/CO2020001981A2/es unknown
-
2023
- 2023-05-01 JP JP2023075458A patent/JP2023106433A/ja active Pending
-
2025
- 2025-06-03 JP JP2025092507A patent/JP2025131681A/ja active Pending
- 2025-06-19 AU AU2025204591A patent/AU2025204591A1/en active Pending